Table 1.

Patient demographics

N%
Gender
 Female4337
 Male7363
Age, y
 24–8863 (mean)
Site of metastatic disease
 Liver2824
 Lung6052
 Brain1614
 Bone1715
 Lymph4942
 Other4539
Lines of treatment prior to ipilimumab
 06959
 13429
 2+1311
LDH at start of ipilimumab195 (median)
Lines of interval treatment between ipilimumab and PD-1
 05951
 ≥15749
Interval radiation1916
Interval BRAF inhibitor2219
LDH at start of anti–PD-1238 (median)
Status at last follow-up
 Alive7766
 Dead3934